What BAG Holding does

BAG Holding GmbH is a German family-owned medical technology holding headquartered in Lich, Hesse, founded in 1947 by Gotthard Sachsenberg and now managed in the third generation by Dr. med. Nicolas Sachsenberg. The group operates through two wholly-owned subsidiaries: BAG Diagnostics GmbH, which develops and sells in vitro diagnostic test systems and reagents for safe blood transfusion and transplantation compatibility (including the 'Mr. Spot' fully automated SSO-based molecular genetic analysis system launched in 2009, HLA typing since 1990, nucleic acid diagnostics since 1996, and biochemical bacteria and fungi detection since 1972); and BAG Health Care GmbH, which operates as a GMP pharmaceutical contract manufacturer specializing in sterile injectables (parenterals) and freeze-dried products (lyophilisates), with freeze-drying capacity quadrupled during 2004-2008.

The group addresses two distinct end markets. For diagnostics, BAG serves hospital laboratories, blood banks, and transplantation centers, where its products support HLA typing for organ and stem cell transplants and screening for transfusion-transmitted infections. For pharmaceutical manufacturing, BAG Health Care serves pharmaceutical companies requiring outsourced sterile drug production capacity. Distribution is direct enterprise sales in both segments, with no third-party resellers disclosed. Approximately 65% of revenue is exported, indicating a global customer footprint rather than a primarily domestic operation, and the corporate site emphasizes 'at home in Lich, present in the world'.

The revenue model is a hybrid of product sales (diagnostic kits, instruments, and reagents) and contract-manufacturing services (parenterals and lyophilisates produced to client specifications). Pricing is not publicly disclosed and is understood to be negotiated contract-by-contract, consistent with B2B pharmaceutical and diagnostic procurement. The group is privately held with no public listing; Hannover Finanz has been the long-term private equity partner since 1989. In 2019, the legacy operating company was reorganized into the current holding-plus-two-operating-units structure. Marketing relies on three corporate websites, a LinkedIn corporate presence, and a dedicated employer-branding job portal rather than third-party channel partners.

Name

BAG Holding

Legal name

BAG Holding GmbH

Website

https://bag-group.com

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

1–10 employees

Short description

BAG Holding GmbH is a German family-owned medical technology holding founded in 1947 and now in its third generation, operating BAG Diagnostics (transfusion and transplantation diagnostic test systems and reagents, including the Mr. Spot automated molecular genetic analyzer) and BAG Health Care (pharmaceutical contract manufacturing of sterile parenterals and lyophilisates), serving global healthcare institutions and pharmaceutical companies with ~65% of revenue from exports.

Ownership category

akta.pro rank

Headquarters

HQ city

Lich

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Products and Reagents: BAG Diagnostics develops and sells test systems and reagents for safe transfusion and transplantation diagnostics, including molecular genetic analysis systems and biochemical detection products.
2. Pharmaceutical Contract Manufacturing: BAG Health Care operates as a pharmaceutical contract manufacturer specializing in production of parenterals (injectable drugs) and lyophilisates (freeze-dried products) for pharmaceutical companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BAG Holding GmbH is a family-owned medical technology group operating through two divisions: BAG Diagnostics develops and sells test systems and reagents for safe transfusion and transplantation diagnostics (including HLA typing, molecular genetic analysis systems, and biochemical detection products), while BAG Health Care is a pharmaceutical contract manufacturer specializing in the production of sterile parenterals (injectable drugs) and lyophilisates (freeze-dried products) for pharmaceutical companies worldwide.

Product overview

BAG Holding GmbH is a family-owned medical technology group founded in 1947, operating as a holding company with two main business divisions: BAG Diagnostics and BAG Health Care. BAG Diagnostics specializes in in vitro diagnostic products including test systems, reagents, and the Mr. Spot automated molecular genetic analysis system for transfusion and transplantation diagnostics. BAG Health Care operates as a pharmaceutical contract manufacturer producing sterile injectables and lyophilizates. The group serves customers worldwide with approximately 65% export quota and has been developing medical solutions for over 75 years.

Differentiator

Problem solved

Functional benefit

Brands

• BAG Diagnostics: Develops test systems and reagents for safe transfusion and transplantation diagnostics
• BAG Health Care

Products and services

• Mr. Spot A fully automated Sequence-Specific Oligonucleotide (SSO) based molecular genetic analysis system for HLA typing and genetic diagnostics, designed for hospital laboratories and clinical diagnostics.
• HLA Products HLA (Human Leukocyte Antigen) products manufactured since 1990 for transplantation diagnostics, used for matching donors and recipients in organ and stem cell transplantation.
• Nucleic Acid Diagnostics Nucleic acid-based diagnostic products for molecular testing, used by hospital laboratories and clinical diagnostics facilities for genetic material detection.
• Biochemical Detection Products (API Diagnostic System) Biochemical diagnostic system for bacterial and fungal identification, used in microbiology laboratories for pathogen detection.
• Culture Media Quality Control

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Recipharm: European CDMO offering sterile fill-finish, lyophilization, and parenteral manufacturing services to pharma companies — closely aligned with BAG Health Care's service offering.
• Bio-Rad Laboratories: Global diagnostics company with significant blood-typing and HLA/immunohematology reagent lines serving hospitals and blood banks, comparable to BAG Diagnostics' transfusion/transplantation focus.
• Immucor: Specialist in transfusion and transplantation diagnostics, offering reagents and instruments for blood typing, antibody screening, and molecular HLA typing — directly overlapping BAG Diagnostics' core transfusion/transplantation portfolio.
• Aenova Group: German-headquartered CDMO with solid dosage forms, sterile liquids, and lyophilization capabilities serving pharmaceutical companies — a regional direct peer to BAG Health Care's parenterals business.
• Quotient Limited: Focused on transfusion diagnostics, offering a broad transfusion medicine portfolio including serological reagent lines and a MosaiQ molecular platform — a near-direct competitor to BAG Diagnostics.
• Siegfried Holding: Swiss CDMO specializing in sterile fill-finish of injectables and APIs, including lyophilized products — a closely comparable pharmaceutical contract manufacturer to BAG Health Care.
• Catalent: Global CDMO with strong capabilities in sterile injectable and lyophilized drug manufacturing, directly comparable to BAG Health Care's parenteral and lyophilisate contract manufacturing services.

Emerging players

• QIAGEN: Molecular diagnostics and sample-preparation technologies company with overlap to BAG Diagnostics' nucleic acid diagnostics and SSO-based molecular testing offerings (Mr. Spot platform).

Broad incumbents

• Lonza Group: World's largest CDMO offering biologics, small molecules, and parenteral fill-finish at global scale; competes with BAG Health Care in sterile injectables/lyophilization but with substantially broader capabilities.
• Thermo Fisher Scientific: Diversified life sciences giant with diagnostics instruments/reagents (including transplant/transfusion-adjacent offerings) and pharmaceutical services, providing broad incumbent competition across both BAG business units.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bag-holding

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BAG Holding